Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cisplatin
/ therapeutic use
Deoxycytidine
/ analogs & derivatives
Dexamethasone
/ therapeutic use
Etoposide
/ therapeutic use
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma
/ drug therapy
Retrospective Studies
Salvage Therapy
Gemcitabine
Autologous stem cell transplant
lymphoma
salvage chemotherapy
stem cell mobilization
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
3
6
2020
medline:
28
4
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
High-dose chemotherapy and autologous stem cell transplant (ASCT) remains a cornerstone of treatment in relapsed/refractory (R/R) aggressive-histology lymphomas. This retrospective study examined efficacy and safety of peripheral blood stem cell (PBSC) mobilization using cyclophosphamide/etoposide and GCSF (CE + GCSF,
Identifiants
pubmed: 32482114
doi: 10.1080/10428194.2020.1762882
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Etoposide
6PLQ3CP4P3
Dexamethasone
7S5I7G3JQL
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM